Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
The combination of umbralisib plus ublituximab, often abbreviated to U2, has promising activity in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) as shown in this ASH 2021 abstract:
Ask the Doctor Question: First diagnosed with CLL in 2007 on Watch and Wait for 6-months, then had FCR light for two rounds. Lymphocytes dropped so significantly that I stopped the
CLL Society Board of Directors Solid, generous, grounded, experienced, compassionate, and business savvy, CLL Society’s Board of Directors fortifies CLL Society’s foundation and directs its laser focus towards actualizing our mission.
CLL Glossary There certainly are many confusing terms in CLL. While this can be overwhelming at first for new patients, we assure you that after a time you will be amazed
Financial Assistance Part 2 Industry Sponsored Financial support programs to help pay for drugs from pharmaceutical companies are constantly changing. The following was taken from their web sites. It is important
What is a Lymph Node? In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be
Managing Side Effects of Oral Targeted Therapies in CLL In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational
Brief Overview of Types of Treatments In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never
Blocking the B-cell receptor (BCR) with ibrutinib and other BTKi drugs has revolutionized care in CLL. PI3K inhibitors also block that same receptor and are remarkably effective in treating CLL. Join Dr. Ian Flinn who will explain how these treatments work, the common side effects, and what role they might play in the future.
One click to our most popular content.
